Compare OEC & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | ALEC |
|---|---|---|
| Founded | 1862 | 2013 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.8M | 275.8M |
| IPO Year | 2014 | 2019 |
| Metric | OEC | ALEC |
|---|---|---|
| Price | $3.84 | $2.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $6.25 | $4.42 |
| AVG Volume (30 Days) | 476.0K | ★ 1.9M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | ★ $1,806,700,000.00 | $21,045,000.00 |
| Revenue This Year | N/A | $900.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.83 | $1.09 |
| 52 Week High | $8.64 | $2.84 |
| Indicator | OEC | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 27.23 | 63.67 |
| Support Level | N/A | $1.90 |
| Resistance Level | $6.06 | $2.65 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 0.00 | 65.24 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.